ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,440,485, issued on Oct. 14, was assigned to Helsinn Healthcare SA (Pazzallo-Lugano, Switzerland).
"Centrally-active ghrelin agonist and medical uses thereof" was invented by Claudio Giuliano (Como, Italy), Claudio Pietra (San Martino Siccomario, Italy), Silvina Garcia Rubio (Princeton, N.J.), Angelo Guainazzi (New York) and Marielle Martinez-Loi (Biasca, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a...